Top

Published in:

01-12-2015 | Research Article

Prognostic significance of the tumour-adjacent tissue in head and neck cancers

Authors: Martina Raudenska, Marketa Sztalmachova, Jaromir Gumulec, Michaela Fojtu, Hana Polanska, Jan Balvan, Marek Feith, Hana Binkova, Zuzana Horakova, Rom Kostrica, Rene Kizek, Michal Masarik

Published in: Tumor Biology | Issue 12/2015

Abstract

Even with significant advances in operative skills and adjuvant therapies, the overall survival of patients suffering with head and neck squamous cancers (HNSCC) is unsatisfactory. Accordingly, no clinically useful prognostic biomarkers have been found yet for HNSCC. Many studies analysed the expression of potential markers in tumour tissues compared to adjacent tissues. Nevertheless, due to the sharing of the same microenvironment, adjacent tissues show molecular similarity to tumour tissues. Thus, gene expression patterns of 94 HNSCC tumorous tissues were compared with 31 adjacent tissues and with 10 tonsillectomy specimens of non-cancer individuals. The genes analysed at RNA level using quantitative RT-PCR and correlated with clinico-pathological conditions were as follows: EGF, EGFR, MKI67, BCL2, BAX, FOS, JUN, TP53, VEGF, FLT1, MMP2, MMP9, MT1A and MT2A. The elevated MT2A, BAX, EGF and JUN expression was associated with the influence of tumour cells on the rearrangement of healthy tissues, as well as a significant shift in the BAX/BCL2 ratio. Our investigation also indicated that adjacent tissues play an important role in cancerogenesis by releasing several tumour-supporting factors such as EGF. A gradual increase in the metallothionein expression, from the lowest one in tonsillectomy samples to the highest ones in tumour samples, suggests that MT expression might be tissue reaction to the presence of tumour cells. The results of this study confirmed the significance of metallothionein in tumori-genesis and gave evidences for its use as a potential HNSCC biomarker. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in prediction of HNSCC progress.

Available only for authorised users

Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86(6):347–63. doi:10.1111/j.0959-9673.2005.00447.x.PubMedPubMedCentral

Goldberg HI, Lockwood SA, Wyatt SW, Crossett LS. Trends and differentials in mortality from cancers of the oral cavity and pharynx in the United States, 1973–1987. Cancer. 1994;74(2):565–72. doi:10.1002/1097-0142(19940715)74:2<565::aid-cncr2820740206>3.0.co;2-i.PubMed

Ghoshal S, Mallick I, Panda N, Sharma SC. Carcinoma of the buccal mucosa: analysis of clinical presentation, outcome and prognostic factors. Oral Oncol. 2006;42(5):533–9. doi:10.1016/j.oraloncology.2005.10.005.PubMed

Jones KR, Lodgerigal RD, Reddick RL, Tudor GE, Shockley WW. Prognostic factors in the recurrence of stage-I and stage-II squamous-cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg. 1992;118(5):483–5.PubMed

Goldson TM, Han Y, Knight KB, Weiss HL, Resto VA. Clinicopathological predictors of lymphatic metastasis in HNSCC: implications for molecular mechanisms of metastatic disease. J Exp Ther Oncol. 2010;8(3):211–21.PubMedPubMedCentral

Fernandez AG, Gimenez N, Fraile M, Gonzalez S, Chabrera C, Torras M, et al. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast. 2012;21(3):366–73. doi:10.1016/j.breast.2012.03.004.

Wallner LP, Frencher SK, Hsu JWY, Chao CR, Nichol MB, Loo RK, et al. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU Int. 2013;111(8):1245–52. doi:10.1111/j.1464-410X.2012.11651.x.PubMed

Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R, et al. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol. 2014;50(3):168–77. doi:10.1016/j.oraloncology.2013.12.008.PubMed

Chandran UR, Dhir R, Ma CQ, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005;5(45). doi:10.1186/1471-2407-5-45.PubMedPubMedCentral

10.

Joshi A, Cao DL. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci Landmark. 2010;15:180–94. doi:10.2741/3614.

11.

Sanz-Pamplona R, Berenguer A, Cordero D, Mollevi DG, Crous-Bou M, Sole X, et al. Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer. 2014;13:46. doi:10.1186/1476-4598-13-46.PubMedPubMedCentral

12.

Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell-death and tissue remodeling during mouse mammary-gland involution. Development. 1992;115(1):49–58.PubMed

13.

Le Bitoux MA, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol. 2008;130(6):1079–90. doi:10.1007/s00418-008-0527-3.PubMed

14.

Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–80. doi:10.1002/ijc.23173.PubMed

15.

Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, Eckschlager T, et al. The role of metallothionein in oxidative stress. Int J Mol Sci. 2013;14(3):6044–66. doi:10.3390/ijms14036044.PubMedPubMedCentral

16.

Sato M, Bremner I. Oxygen free-radicals and metallothionein. Free Radic Biol Med. 1993;14(3):325–37. doi:10.1016/0891-5849(93)90029-t.PubMed

17.

Sochor J, Hynek D, Krejcova L, Fabrik I, Krizkova S, Gumulec J, et al. Study of metallothionein role in spinocellular carcinoma tissues of head and neck tumours using brdicka reaction. Int J Electrochem Sci. 2012;7(3):2136–52.

18.

Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, Agnantis NJ. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract. 1999;195(12):809–14.PubMed

19.

Dutsch-Wicherek M, Lazar A, Tomaszewska R, Kazmierczak W, Wicherek L. Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment. Cell Tissue Res. 2013;352(2):341–9. doi:10.1007/s00441-013-1566-1.PubMedPubMedCentral

20.

Gumulec J, Raudenska M, Adam V, Kizek R, Masarik M. Metallothionein—Immunohistochemical cancer biomarker: a meta-analysis. Plos One. 2014;9(1). doi:10.1371/journal.pone.0085346.

21.

Inoue K-i, Takano H, Shimada A, Satoh M. Metallothionein as an anti-inflammatory mediator. Mediat Inflamm. 2009. doi:10.1155/2009/101659.

22.

Inoue KI, Takano H, Yanagisawa R, Sakurai M, Ichinose T, Sadakane K, et al. Role of metallothionein in antigen-related airway inflammation. Exp Biol Med. 2005;230(1):75–81.

23.

Tate DJ, Newsome DA, Oliver PD. Metallothionein shows an age-related decrease in human macular retinal-pigment epithelium. Invest Ophthalmol Vis Sci. 1993;34(7):2348–51.PubMed

24.

Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, et al. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuroendocrinol Lett. 2005;26(5):567–74.PubMed

25.

Walentowicz-Sadlecka M, Koper A, Krystyna G, Koper K, Basta P, Mach P, et al. The analysis of metallothionein immunoreactivity in stromal fibroblasts and macrophages in cases of uterine cervical carcinoma with respect to both the local and distant spread of the disease. Am J Reprod Immunol. 2013;70(3):253–61. doi:10.1111/aji.12120.PubMed

26.

Colella S, Richards KL, Bachinski LL, Baggerly KA, Tsavachidis S, Lang JC, et al. Molecular signatures of metastasis in head and neck cancer. Head Neck J Sci Spec Head Neck. 2008;30(10):1273–83. doi:10.1002/hed.20871.

27.

Wlostowski T. Involvement of metallothionein and copper in cell-proliferation. Biometals. 1993;6(2):71–6. doi:10.1007/bf00140106.PubMed

28.

Saadeddin A, Babaei-Jadidi R, Spencer-Dene B, Nateri AS. The links between transcription, beta-catenin/jnk signaling, and carcinogenesis. Mol Cancer Res. 2009;7(8):1189–96. doi:10.1158/1541-7786.mcr-09-0027.PubMed

29.

Li W, Wu C-L, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol. 2007;171(4):1189–98. doi:10.2353/ajpath.2007.070285.PubMedPubMedCentral

30.

Jameson MJ, Beckler AD, Taniguchi LE, Allak A, VanWagner LB, Lee NG, et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther. 2011;10(11):2124–34. doi:10.1158/1535-7163.mct-11-0294.PubMedPubMedCentral

31.

Buchheit CL, Weigel KJ, Schafer ZT. OPINION cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;14(9):632–41. doi:10.1038/nrc3789.PubMed

32.

Skvortsov S, Dudas J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, et al. Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC). Br J Cancer. 2014;110(11):2677–87. doi:10.1038/bjc.2014.221.PubMedPubMedCentral

33.

Couture C, Raybaud-Diogene H, Tetu B, Bairati I, Murry D, Allard J, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94(3):713–22. doi:10.1002/cncr.10232.PubMed

34.

Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle. 2013;12(9):1371–84. doi:10.4161/cc.24092.PubMedPubMedCentral

35.

Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer. 1999;84(6):573–9. doi:10.1002/(sici)1097-0215(19991222)84:6<573::aid-ijc6>3.0.co;2-r.PubMed

36.

Voehringer DW, McConkey DJ, McDonnell TJ, Brisbay S, Meyn RE. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci U S A. 1998;95(6):2956–60. doi:10.1073/pnas.95.6.2956.PubMedPubMedCentral

37.

Chen Q, Chai YC, Mazumder S, Jiang C, Macklis R, Chisolm GM, et al. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ. 2003;10(3):323–34. doi:10.1038/sj.cdd.4401148.PubMed

38.

DelBufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J. 1997;11(12):947–53.

39.

Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett. 1998;440(3):419–24. doi:10.1016/s0014-5793(98)01494-x.PubMed

40.

Choi J, Choi K, Benveniste EN, Hong YS, Lee JH, Kim J, et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res. 2005;65(13):5554–60. doi:10.1158/0008-5472.can-04-4570.PubMed

41.

Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol. 2009;9(4):389–95. doi:10.1016/j.coph.2009.06.005.PubMedPubMedCentral

42.

Liu CJ, Chang KW, Lin SC, Cheng HW. Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma. Oral Oncol. 2009;45(10):920–5. doi:10.1016/j.oraloncology.2009.04.007.PubMed

43.

Yuce I, Bayram A, Cagli S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol. 2011;32(2):141–6. doi:10.1016/j.amjoto.2010.01.001.PubMed

44.

Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009;28(30):2723–37. doi:10.1038/onc.2009.128.PubMed

45.

Yang MH, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene. 2007;26(10):1459–67. doi:10.1038/sj.onc.1209929.PubMed

46.

Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999;35(3):227–33. doi:10.1016/s1368-8375(99)00004-4.PubMed

47.

Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta Rev Cancer. 2005;1755(1):37–69. doi:10.1016/j.bbcan.2005.03.001.

48.

Fullar A, Kovalszky I, Bitsche M, Romani A, Schartinger VH, Sprinzl GM, et al. Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma. Exp Cell Res. 2012;318(13):1517–27. doi:10.1016/j.yexcr.2012.03.023.PubMedPubMedCentral

49.

Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer. 2013;4(1):66–83. doi:10.7150/jca.5112.PubMedPubMedCentral

50.

London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther. 2003;10(11):823–32. doi:10.1038/sj.cgt.7700642.PubMed

51.

Farina AR, Mackay AR. Gelatinase B/MMP-9 in tumour pathogenesis and progression. Cancers (Basel). 2014;6(1):240–96. doi:10.3390/cancers6010240.

52.

Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9. doi:10.1016/j.ccr.2009.01.021.PubMedPubMedCentral

53.

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31. doi:10.1016/j.ccr.2009.01.027.PubMedPubMedCentral

54.

Van Limbergen EJ, Zabrocki P, Porcu M, Hauben E, Cools J, Nuyts S. FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinoma. Acta Oncol. 2014;53(5):637–45. doi:10.3109/0284186x.2013.835493.PubMed

55.

Ito TK, Ishii G, Chiba H, Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene. 2007;26(51):7194–203. doi:10.1038/sj.onc.1210535.PubMed

56.

Lucas JT, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. 2010;29(31):4449–59. doi:10.1038/onc.2010.185.PubMedPubMedCentral

57.

Smirnova T, Adomako A, Locker J, Van Rooijen N, Prystowsky MB, Segall JE. In vivo invasion of head and neck squamous cell carcinoma cells does not require macrophages. Am J Pathol. 2011;178(6):2857–65. doi:10.1016/j.ajpath.2011.02.030.PubMedPubMedCentral

58.

Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72. doi:10.1200/jco2005.04.8306.PubMed

59.

Grandis JR, Tweardy DJ. Elevated levels of transforming growth-factor-alpha and epidermal growth-factor receptor messenger-RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579–84.PubMed

60.

Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4(1):13–20.

61.

Ang KK, Berkey BA, Tu XY, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350–6.PubMed

62.

Park BJ, Chiosea SI, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark. 2011;9(1–6):325–39. doi:10.3233/cbm-2011-0163.

Title: Prognostic significance of the tumour-adjacent tissue in head and neck cancers
Authors: Martina Raudenska
Marketa Sztalmachova
Jaromir Gumulec
Michaela Fojtu
Hana Polanska
Jan Balvan
Marek Feith
Hana Binkova
Zuzana Horakova
Rom Kostrica
Rene Kizek
Michal Masarik
Publication date: 01-12-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3755-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2015

Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer

Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer

Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein

Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis

The emerging role of Nemo-like kinase (NLK) in the regulation of cancers

Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer